Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Pharmacotherapy

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.28.11.1354PMID 18956996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New oral Xa and IIa inhibitors: updates on clinical trial results

  2008cited by this paper
• Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

  2008cited by this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Dabigatran versus enoxaparin after total hip replacement.

  2007cited by this paper
• Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

  2007cited by this paper
• Dabigatran versus enoxaparin after total hip replacement.

  2007cited by this paper
• Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

  2007cited by this paper
• Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation

  2007cited by this paper
• Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.

  2007cited by this paper
• The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

  2007cited by this paper
• Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

  2007cited by this paper
• Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery

  2007cited by this paper
• Individualizing warfarin therapy.

  2007cited by this paper
• Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation

  2007cited by this paper
• Beyond Unfractionated Heparin and Warfarin: Current and Future Advances

  2007cited by this paper
• Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.

  2006cited by this paper
• A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators.

  2006cited by this paper
• A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era...

  2005cited by this paper
• Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

  2005cited by this paper
• Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin

  2005cited by this paper
• Ximelagatran: an orally active direct thrombin inhibitor.

  2005cited by this paper
• A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial

  2005cited by this paper
• Direct thrombin inhibitors.

  2005cited by this paper
• The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Direct Thrombin Inhibitors for Anticoagulation

  2004cited by this paper
• Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis

  2004cited by this paper
• Pharmacist‐Provided Anticoagulation Management in United States Hospitals: Death Rates, Length of Stay, Medicare Charges, Bleeding Complications, and Transfusions

  2004cited by this paper
• Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I

  2004cited by this paper
• Red book : pharmacy's fundamental reference

  2004cited by this paper
• The decision to anticoagulate: Assessing whether benefits outweigh the risks for patients with atrial fibrillation

  2004cited by this paper
• Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.

  2003cited by this paper
• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  2003cited by this paper
• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  2003cited by this paper
• Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

  2003cited by this paper
• Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

  2003cited by this paper
• Secondary prophylaxis with warfarin for venous thromboembolism.

  2003cited by this paper
• Targeting thrombin--rational drug design from natural mechanisms.

  2003cited by this paper
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

  2003cited by this paper
• Serine proteases as targets for antithrombotic therapy

  2003cited by this paper
• Warfarin, aspirin, or both after myocardial infarction.

  2002cited by this paper
• Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

  2002cited by this paper
• Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

  2002cited by this paper
• Structure-based design of novel potent nonpeptide thrombin inhibitors.

  2002cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• Optimization of Inpatient Warfarin Therapy: Impact of Daily Consultation by a Pharmacist-Managed Anticoagulation Service

  2000cited by this paper
• Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.

  1998cited by this paper

• Bibliometric Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACS) in the Prevention of Venous Thrombosis and Pulmonary Embolism

  2025cites this paper
• Polymorphic Stability and Enhanced Drug Release of Dabigatran Etexilate Mesylate in Mesoporous Silica-Based Liquisolid Systems- Formulation and In Vitro Evaluation

  2025cites this paper
• Discovery of an autoinhibited conformation in mesotrypsin reveals a strategy for selective serine protease inhibition

  2025cites this paper
• Anticoagulation in the Management of Acute Pulmonary Embolism—A Review

  2024cites this paper
• Ovulation provides excessive coagulation and hepatocyte growth factor signals to cause postoperative intraabdominal adhesions

  2024cites this paper
• The impact of chronic kidney disease on prognosis in acute stroke: unraveling the pathophysiology and clinical complexity for optimal management

  2024influential citation
• Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.

  2023cites this paper
• Pathophysiological Role of Microglial Activation Induced by Blood-Borne Proteins in Alzheimer’s Disease

  2023cites this paper
• Pulsed laser irradiation induces the generation of alloy cluster ions for the screening of protease activity.

  2022cites this paper
• Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review.

  2022cites this paper
• Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry study.

  2022cites this paper
• Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation

  2021cites this paper
• Dabigatran Etexilate

  2021cites this paper
• Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization

  2019cites this paper
• USE OF ANTICOAGULANTS IN CEREBRAL VASCULAR PATHOLOGY

  2019cites this paper
• Thromboprophylaxis

  2019cites this paper
• Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism

  2019cites this paper
• Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation

  2018cites this paper
• Anticoagulants oraux directs

  2018cites this paper
• The peri-procedural management of new oral anti-coagulants (NOACs) in interventional electrophysiology

  2018cites this paper
• Anticoagulants and Treatment of Venous Thromboembolism

  2018cites this paper
• Thrombin Receptor Agonist Peptide–Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran

  2018cites this paper
• Bilateral subconjunctival hemorrhage secondary to abciximab use: case report

  2017cites this paper
• Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring

  2017cites this paper
• Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients

  2017cites this paper
• Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).

  2017cites this paper
• Monitoring and Reversal of Oral Anticoagulation in Hospitalized Patients

  2017cites this paper
• Novel dabigatran etexilate hemisuccinate-loaded polycap: Physicochemical characterisation and in vivo evaluation in beagle dogs.

  2017cites this paper
• The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency

  2016cites this paper
• Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis ( Review )

  2016cites this paper
• Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery

  2016cites this paper
• Treatment of Venous Thromboembolism With New Anticoagulant Agents.

  2016cites this paper
• Recent Advances in the Pharmacological Management of Atrial Fibrillation

  2016cites this paper
• Anticoagulant Therapy to Prevent Embolization

  2016cites this paper
• Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.

  2015cites this paper
• Neue Therapieoptionen zur Behandlung der Lungenembolie: Studienlage und Stellenwert der direkten oralen Antikoagulantien

  2015cites this paper
• Pharmacist-managed clinics for patient education and counseling in Japan: current status and future perspectives

  2015cites this paper
• Anticoagulants and Antiplatelet Agents in Pregnancy

  2015cites this paper
• Analysis of the influence of dabigatran on coagulation factors and inhibitors

  2015cites this paper
• [New therapeutic approaches to pulmonary embolism: trials' results and significance of direct oral anticoagulants].

  2015cites this paper
• Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.

  2015cites this paper
• Toxin-induced coagulopathy.

  2014cites this paper
• Analysis of Novel Anticoagulants for Atrial Fibrillation - Pharmacokinetics and Pharmacological Considerations

  2014cites this paper
• New Anticoagulants and Antiplatelet Agents: A Primer for the Clinical Gastroenterologist

  2014cites this paper
• Abstracts and Highlight Papers of the 33rd Annual European Society of Regional Anaesthesia & Pain Therapy (ESRA) Congress 2014: Invited Speaker Highlight Papers

  2014cites this paper
• Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.

  2014cites this paper
• Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty

  2014cites this paper
• Cardiovascular and biochemical studies on the effects of thrombin and dabigatran and the interaction with vasopressor molecules

  2014cites this paper
• New oral anticoagulants for the treatment of venous thromboembolism.

  2013cites this paper
• Formulations pharmaceutiques orales comprenant du dabigatran

  2013cites this paper
• "Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan.

  2013cites this paper
• The Pharmacology and Therapeutic Use of Dabigatran Etexilate

  2013cites this paper
• Case Report: Dabigatran-Associated Gynecologic Bleeding

  2013cites this paper
• Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

  2013cites this paper
• Anticoagulants: A Review of the Pharmacology, Dosing, and Complications

  2013cites this paper
• Sangrado rectal tras la administración de Dabigatrán

  2013cites this paper
• Pharmacogenetics of Oral Anticoagulants

  2013cites this paper
• New Drugs for Thromboprophylaxis: Apixaban, Dabigatran, Rivaroxaban

  2013cites this paper
• Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.

  2013cites this paper
• Nuevos anticoagulantes orales en la prevención de fenómenos tromboembólicos en la fibrilación auricular no valvular

  2013cites this paper
• The perioperative management of new direct oral anticoagulants: a question without answers

  2013cites this paper
• Orale pharmazeutische Formulierungen mit Dabigatran

  2013cites this paper
• Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism.

  2013cites this paper
• Effective elimination of dabigatran by haemodialysis

  2013cites this paper
• New Anticoagulant: Dabigatran

  2013cites this paper
• Monitoring strategies for patients treated with the new oral anticoagulants and the need for laboratory evaluation of hemostasis

  2013cites this paper
• Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa).

  2013cites this paper
• Direct Thrombin Inhibitors

  2012cites this paper
• Impact of dabigatran on a large panel of routine or specific coagulation assays

  2012cites this paper
• Abstracts and Highlight Papers of the 31st Annual European Society of Regional Anaesthesia (ESRA) Congress 2012

  2012cites this paper
• Epidural Hematoma and Intraoperative Hemorrhage in a Spine Trauma Patient on Pradaxa (Dabigatran)

  2012cites this paper
• El nuevo anticoagulante dabigatran es una alternativa a la warfarina y las heparinas de bajo peso molecular

  2012cites this paper
• The identification and management of heparin-induced thrombocytopenia in the vascular patient.

  2012cites this paper
• El nuevo anticoagulante dabigatran es una alternativa a la warfarina y las heparinas de bajo peso molecular

  2012cites this paper
• Drug review – Dabigatran for stroke prevention in atrial fibrillation

  2012cites this paper
• New oral anticoagulants: an alternative to warfarin.

  2012cites this paper
• Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment

  2012cites this paper
• Anticoagulation Review

  2012cites this paper
• Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians

  2012cites this paper
• Costs and clinical consequences of suboptimal atrial fibrillation management

  2012cites this paper
• The Role of Apixaban for Venous and Arterial Thromboembolic Disease

  2011cites this paper
• Efficacy and safety of novel anticoagulants compared with established agents

  2011influential citation
• Antithrombotic Therapy for Secondary Stroke Prevention

  2011cites this paper
• A retrospective assessment comparing pharmacist-managed anticoagulation clinic with physician management using international normalized ratio stability

  2011cites this paper
• AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction.

  2011cites this paper
• Dabigatran Etexilate A New Oral Thrombin Inhibitor

  2011cites this paper
• Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty

  2011cites this paper
• Dabigatran Etexilate: The First Oral Anticoagulant Available in the United States Since Warfarin

  2011influential citation
• Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation

  2011cites this paper
• New anticoagulants in critical care settings.

  2011cites this paper
• Concise Guide to Hematology

  2011influential citation
• Novos Anticoagulantes Orais: Inividores Directos dos Factores IIa e Xa.

  2011influential citation
• Novos anticoagulantes em cuidados intensivos

  2011cites this paper
• Dabigatran Versus Warfarin

  2011cites this paper
• Dabigatran etexilate: A novel oral direct thrombin inhibitor.

  2011influential citation
• New Drugs and Technologies Dabigatran Etexilate A New Oral Thrombin Inhibitor

  2011cites this paper
• Intravenous heparin, low-molecular-weight heparins, and thrombin antagonists

  2011cites this paper
• Warfarin-related nephropathy: another newly recognized complication of an old drug.

  2011cites this paper
• Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease

  2011cites this paper
• New Therapy Update

  2011influential citation